Skip to main content
BAYRY
OTC Life Sciences

Bayer Wins Approval for Asundexian, a First-in-Class Stroke-Prevention Drug

Tom Rudovsky · Reported by Seeking Alpha
Sentiment info
Positive
Importance info
8
Price
$15.91
Mkt Cap
$60.833B
52W Low
$7.49
52W High
$15.97
52W Position info
112% above low
Off High info
at 52W high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

BAYRY has more than doubled off its 52-week low of $7.49.

Summary

Bayer secured approval for asundexian, a Factor XIa inhibitor aimed at cutting stroke risk. This is a genuine pipeline win for a company whose pharma story has been dominated by litigation overhang, and it lands with the stock trading near its 52-week high of $15.97, so the market has already been warming to the name. Asundexian is the key late-stage asset Bayer has been counting on to offset patent cliffs in its older drugs, so a regulatory green light is the outcome that matters most for the pharma segment. The OTC ADR BAYRY is the primary listing here; BAYZF is the same underlying German shares.

At the time of this announcement, BAYRY was trading at $15.91 on OTC in the Life Sciences sector, with a market capitalization of approximately $60.8B. The 52-week trading range was $7.49 to $15.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

BAYRY - Latest Insights